Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

984 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment.
Lamberts LE, Menke-van der Houven van Oordt CW, ter Weele EJ, Bensch F, Smeenk MM, Voortman J, Hoekstra OS, Williams SP, Fine BM, Maslyar D, de Jong JR, Gietema JA, Schröder CP, Bongaerts AH, Lub-de Hooge MN, Verheul HM, Sanabria Bohorquez SM, Glaudemans AW, de Vries EG. Lamberts LE, et al. Among authors: de vries eg, de jong jr. Clin Cancer Res. 2016 Apr 1;22(7):1642-52. doi: 10.1158/1078-0432.CCR-15-1272. Epub 2015 Nov 20. Clin Cancer Res. 2016. PMID: 26589435
Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement.
Faneyte IF, Peterse JL, Van Tinteren H, Pronk C, Bontenbal M, Beex LV, van der Wall E, Richel DJ, Nooij MA, Voest EE, Hupperets P, Ten Vergert EM, de Vries EG, Rodenhuis S, van de Vijver MJ. Faneyte IF, et al. Among authors: de vries eg. Clin Cancer Res. 2004 Jul 1;10(13):4457-63. doi: 10.1158/1078-0432.CCR-03-0054. Clin Cancer Res. 2004. PMID: 15240537 Clinical Trial.
Preclinical characterisation of 111In-DTPA-trastuzumab.
Lub-de Hooge MN, Kosterink JG, Perik PJ, Nijnuis H, Tran L, Bart J, Suurmeijer AJ, de Jong S, Jager PL, de Vries EG. Lub-de Hooge MN, et al. Among authors: de vries eg, de jong s. Br J Pharmacol. 2004 Sep;143(1):99-106. doi: 10.1038/sj.bjp.0705915. Epub 2004 Aug 2. Br J Pharmacol. 2004. PMID: 15289297 Free PMC article.
The dilemma of the strive for apoptosis in oncology: mind the heart.
Perik PJ, de Vries EG, Gietema JA, van der Graaf WT, Sleijfer DT, Suurmeijer AJ, van Veldhuisen DJ. Perik PJ, et al. Among authors: de vries eg. Crit Rev Oncol Hematol. 2005 Feb;53(2):101-13. doi: 10.1016/j.critrevonc.2004.10.001. Crit Rev Oncol Hematol. 2005. PMID: 15661561 Review.
Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer.
Hoekstra R, de Vos FY, Eskens FA, Gietema JA, van der Gaast A, Groen HJ, Knight RA, Carr RA, Humerickhouse RA, Verweij J, de Vries EG. Hoekstra R, et al. Among authors: de vries eg, de vos fy. J Clin Oncol. 2005 Aug 1;23(22):5188-97. doi: 10.1200/JCO.2005.05.013. J Clin Oncol. 2005. PMID: 16051960 Clinical Trial.
984 results